CONNECT WITH US
HealthTech

HealthTech

First successful human challenge model for dengue serotype 4 could speed vaccine and drug testing

Medical Xpress logo

Published on

Add as a preferred source on Google
First successful human challenge model for dengue serotype 4 could speed vaccine and drug testing

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Researchers at the University of Maryland School of Medicine (UMSOM) and the Institute of Human Virology (IHV) have developed the first successful human challenge model for dengue serotype 4, a major advance that could speed the development of new drugs and vaccines against a strain of the dengue virus that remains difficult to study.

The dengue virus is a flavivirus. Each participant received a single injection under the skin containing 95 plaque-forming units of the challenge virus—a very low dose by the standards of earlier dengue challenge studies, which used at least seven times more virus.

Participants were checked daily for symptoms, had blood drawn regularly and were housed in a local hotel while the virus was detectable in their blood so that local mosquitoes could not pick it up and spread it.

The study ran at the University of Maryland School of Medicine in Baltimore between April 2022 and December 2023.

All 14 participants developed detectable virus in their blood and mild-to-moderate dengue symptoms. The most common symptoms were rash and fatigue, which every participant developed, followed by headaches.

"The study also offered us a rare opportunity to examine how immunity develops and persists following dengue infection," said Joel Chua, Associate Professor of Medicine at the Institute of Human Virology, UMSOM.

"We gained new insights into the immune system's response at the earliest time points after dengue exposure and also found evidence that the immune response generated by an initial DENV-4 exposure can provide durable, serotype-specific protection at least one year later."


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.